Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 743, Issue -, Pages 42-47Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2014.09.022
Keywords
Glia; Neurodegeneration; Neurotoxicity; Sigma receptors
Categories
Funding
- National Institute on Drug Abuse [R01 DA011979, R01 DA013978, R01 DA023205]
- National Institute of Neurological Disorders and Stroke [T32 NS007491]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007491] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013978, R01DA023205, R01DA011979] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Sigma receptors comprise a unique family of proteins that have been implicated in the pathophysiology and treatment of many central nervous system disorders, consistent with their high level of expression in the brain and spinal cord. Mounting evidence indicate that targeting sigma receptors may be particularly beneficial in a number of neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, stroke, methamphetamine neurotoxicity, Huntington's disease, amyotrophic lateral sclerosis, and retinal degeneration. In this perspective, a brief overview is given on sigma receptors, followed by a focus on common mechanisms of neurodegeneration that appear amenable to modulation by sigma receptor ligands to convey neuroprotective effects and/or restorative functions. Within each of the major mechanisms discussed herein, the neuroprotective effects of sigma ligands are summarized, and when known, the specific sigma receptor subtype(s) involved are identified. Together, the literature suggests sigma receptors may provide a novel target for combatting neurodegenerative diseases through both neuronal and glial mechanisms. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available